Airway and systemic effects of hydrofluoroalkane formulations of high-dose ciclesonide and fluticasone in moderate persistent asthma

Chest

Volumn 127, Issue 3, 2005, Pages 851-860

  Lee, Daniel K C ^a   Fardon, Thomas C ^a   Bates, Caroline E ^a   Haggart, Kay ^a   McFarlane, Lesley C ^a   Lipworth, Brian J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Asthma; Ciclesonide; Exhaled nitric oxide; Fluticasone propionate; Human corticotropin releasing factor; Methacholine bronchial challenge; Mini Asthma Quality of Life Questionnaire; Overnight 10 h urinary cortisol

Indexed keywords

CICLESONIDE; CORTICOTROPIN RELEASING FACTOR; FLUORINATED HYDROCARBON; FLUTICASONE PROPIONATE; MONTELUKAST; NITRIC OXIDE; PLACEBO; SALMETEROL; SALMETEROL XINAFOATE; ANDROSTANE DERIVATIVE; BRONCHODILATING AGENT; DIAGNOSTIC AGENT; FLUTICASONE; HYDROCORTISONE; METHACHOLINE CHLORIDE; PREGNANE DERIVATIVE;

ADULT; ARTICLE; ASTHMA; BRONCHUS HYPERREACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG FORMULATION; DRUG MEGADOSE; FEMALE; FIRST PASS EFFECT; FORCED EXPIRATORY VOLUME; HORMONE RESPONSE; HUMAN; HYDROCORTISONE URINE LEVEL; MALE; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; BLOOD; BREATH ANALYSIS; COMPARATIVE STUDY; INHALATION TEST; INHALATIONAL DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PEAK EXPIRATORY FLOW; SPIROMETRY; URINE;

ADMINISTRATION, INHALATION; ANDROSTADIENES; ASTHMA; BREATH TESTS; BRONCHIAL HYPERREACTIVITY; BRONCHIAL PROVOCATION TESTS; BRONCHODILATOR AGENTS; CORTICOTROPIN-RELEASING HORMONE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROCORTISONE; MALE; METHACHOLINE CHLORIDE; MIDDLE AGED; NITRIC OXIDE; PEAK EXPIRATORY FLOW RATE; PREGNENEDIONES; QUALITY OF LIFE; SPIROMETRY;

EID: 15844377108     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.127.3.851     Document Type: Article

References (29)

1. Allen DB, Bielory L, Derendorf H, et al. Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol 2003; 112:S1-S40
2. Weinbrenner A, Huneke D, Zschiesche M, et al. Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide. J Clin Endocrinol Metab 2002; 87:2160-2163
3. Kaliner M, White M, Chervinsky P, et al. Ciclesonide, a novel inhaled corticosteroid, does not suppress hypothalamic-pituitary-adrenal-axis function [abstract]. Allergy Clin Immunol Int 2003; 15(suppl):O17
4. Pauwels RA, Derom E, van de Velde V, et al. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and PC20 for adenosine in asthma patients [abstract]. Am J Respir Crit Care Med 2002; 165(suppl):G84
5. Lipworth BJ, Seckl JR. Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids. Thorax 1997; 52:476-482
6. Schlaghecke R, Kornely E, Santen RT, et al. The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone. N Engl J Med 1992; 326:226-230
7. Sont JK, Willems LN, Bel EH, et al. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment: the AMPUL Study Group. Am J Respir Crit Care Med 1999; 159:1043-1051
8. Wilson AM, Lipworth BJ. Dose-response evaluation of the therapeutic index for inhaled budesonide in patients with mild-to-moderate asthma. Am J Med 2000; 108:269-275
9. Lee DK, Haggart K, Currie GP, et al. Effects of hydrofluoroalkane formulations of ciclesonide 400 μg once daily vs fluticasone 250 μg twice daily on methacholine hyper-responsiveness in mild-to-moderate persistent asthma. Br J Clin Pharmacol 2004; 58:26-33
10. National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma; update on selected topics 2002. J Allergy Clin Immunol 2002; 110:5141-8219
11. British Thoracic Society, Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax 2003; 58(suppl):i1-i94
12. Crapo RO, Casaburi R, Coates AL, et al. Guidelines for methacholine and exercise challenge testing-1999: this official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Grit Care Med 2000; 161:309-329
13. Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med 1995; 152:1107-36
14. Kharitonov S, Alving K, Barnes PJ. Exhaled and nasal nitric oxide measurements: recommendations; the European Respiratory Society Task Force. Eur Respir J 1997; 10:1683-1693
15. Juniper EF, Guyatt GH, Cox FM, et al. Development and validation of the Mini Asthma Quality of Life Questionnaire. Eur Respir J 1999; 14:32-38
16. Weiner P, Berar-Yanay N, Davidovich A, et al. Nocturnal Cortisol secretion in asthmatic patients after inhalation of fluticasone propionate. Chest 1999; 116:931-934
17. Bratsche MH, Bratsche IC, Munawar M, et al. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomized crossover study. Lancet 2000; 356:556-561
18. Harrison TW, Tattersfield AE. Plasma concentrations of fluticasone propionate and budesonide following inhalation from dry powder inhalers by healthy and asthmatic subjects. Thorax 2003; 58:258-260
19. Lee DK, Bates CE, Currie GP, et al. Effects of high-dose inhaled fluticasone propionate on the hypothalamic-pituitary-adrenal axis in asthmatic patients with severely impaired lung function. Ann Allergy Asthma Immunol 2004; 93:253-258
20. Clark DJ, Lipworth BJ. Evaluation of corticotropin releasing factor stimulation and basal markers of hvpothalamic-pituitary-adrenal axis suppression in asthmatic patients. Chest 1997; 112:1248-1252
21. Kunka R, Andrews S, Pimazzoni M, et al. From hydrofluoroalkane pressurized metered dose inhalers (pMDIs) and comparability with chlorofluorocarbon pMDIs. Respir Med 2000; 94(suppl):S10-S16
22. Wilson AM, Sims EJ, Orr LC, et al. Differences in lung bioavailability between different propellants for fluticasone propionate. Lancet 1999; 354:1357-1358
23. Fowler SJ, Orr LC, Sims EJ, et al. Therapeutic ratio of hydrofluoroalkane and chlorofluorocarbon formulations of fluticasone propionate. Chest 2002; 122:618-623
24. Ayres JG, Millar AB, Sykes AP. Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma: UK Study Group. Respir Med 2000; 94(suppl):S42-S50
25. Wilson AM, Sims EJ, Lipworth BJ. Dose response with fluticasone propionate on adrenocortical activity and recovery of basal and stimulated responses after stopping treatment. Clin Endocrinol 1999; 50:329-335
26. Currie GP, Fowler SJ, Lipworth BJ. Dose response of inhaled corticosteroids on bronchial hyperresponsiveness: a meta-analysis. Ann Allergy Asthma Immunol 2003; 90:194-198
27. Dempsey OJ, Kennedy G, Lipworth BJ. Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with mild persistent asthma. J Allergy Clin Immunol 2002; 109:68-74
28. Sovijarvi AR, Haahtela T, Ekroos HJ, et al. Sustained reduction in bronchial hyperresponsiveness with inhaled fluticasone propionate within three days in mild asthma: time course after onset and cessation of treatment. Thorax 2003; 58:500-504
29. Currie GP, Lee DK, Dempsey OJ, et al. A proof of concept study to evaluate putative benefits of montelukast in moderate persistent asthmatics. Br J Clin Pharmacol 2003; 55:609-615